综述

超声新技术在预测乳腺癌分子标志物中的应用进展

展开
  • 上海交通大学医学院附属瑞金医院超声科,上海 200025

收稿日期: 2020-02-05

  网络出版日期: 2020-06-25

基金资助

上海市卫生健康委员会青年项目(20174Y0069);国家自然科学基金面上项目(81471669)

本文引用格式

罗婷, 周建桥 . 超声新技术在预测乳腺癌分子标志物中的应用进展[J]. 诊断学理论与实践, 2020 , 19(03) : 325 -328 . DOI: 10.16150/j.1671-2870.2020.03.022

参考文献

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1):7-30.
[2] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
[3] Prat A, Pineda E, Adamo B, et al. Clinical implications of the intrinsic molecular subtypes of breast cancer[J]. Breast, 2015, 24( Suppl 2):S26-S35.
[4] Tremont A, Lu J, Cole JT. Endocrine therapy for early breast cancer: Updated review[J]. Ochsner J, 2017, 17(4):405-411.
[5] Ma CX, Bose R, Ellis MJ. Prognostic and predictive biomarkers of endocrine responsiveness for estrogen receptor positive breast cancer[J]. Adv Exp Med Biol, 2016, 882:125-154.
[6] Asif HM, Sultana S, Ahmed S, et al. HER-2 positive breast cancer-a mini-review[J]. Asian Pac J Cancer Prev, 2016, 17(4):1609-1615.
[7] Moasser MM, Krop IE. The evolving landscape of HER2 targeting in breast cancer[J]. Jama Oncol, 2015, 1(8):1154-1161.
[8] Wang W, Wu J, Zhang P, et al. Prognostic and predictive value of Ki-67 in triple-negative breast cancer[J]. Oncotarget, 2016, 7(21):31079-31087.
[9] Mb A, Sb E, Fl G, et al. AJCC cancer staging manual[M]. 8th ed. New York: Springer, 2016:589-628.
[10] 中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2019年版)[J]. 中国癌症杂志, 2019, 29(8):609-679.
[11] 彭晓静, 李奥, 叶新华, 等. 应变式弹性成像与剪切波弹性成像技术鉴别诊断乳腺良恶性病灶的价值比较[J]. 中华医学超声杂志(电子版), 2016, 13(12):942-947.
[12] You Y, Song Y, Li SX, et al. Quantitative and qualitative evaluation of breast cancer prognosis: A sonographic elastography study[J]. Med Sci Monit, 2019, 25:9272-9279.
[13] Hayashi M, Yamamoto Y, Sueta A, et al. Associations between elastography findings and clinicopathological factors in breast cancer[J]. Medicine (Baltimore), 2015, 94(50):e2290.
[14] Chang JM, Park IA, Lee SH, et al. Stiffness of tumours measured by shear-wave elastography correlated with subtypes of breast cancer[J]. Eur Radiol, 2013, 23(9):2450-2458.
[15] Youk JH, Gweon HM, Son EJ, et al. Shear-wave elastography of invasive breast cancer: correlation between quantitative mean elasticity value and immunohistochemi-cal profile[J]. Breast Cancer Res Treat, 2013, 138(1):119-126.
[16] Brocklehurst D, Wilde CE, Finbow JA, et al. Relative importance of estrogen and progesterone receptor assays as prognostic indicators in primary breast cancer: a short-term study[J]. Clin Chem, 1989, 35(2):238-240.
[17] Au FWF, Ghai S, Lu FI, et al. Quantitative shear wave elastography: correlation with prognostic histologic features and immunohistochemical biomarkers of breast cancer[J]. Acad Radiol, 2015, 22(3):269-277.
[18] Choi WJ, Kim HH, Cha JH, et al. Predicting prognostic factors of breast cancer using shear wave elastography[J]. Ultrasound Med Biol, 2014, 40(2):269-274.
[19] Gonzalez-Sistal A, Baltasar-Sánchez A, Menéndez P, et al. Breastfeeding and immunohistochemical expression of ki-67, p53 and BCL2 in infiltrating lobular breast carcinoma[J]. PloS One, 2016, 11(3):e151093.
[20] Raja R, Kale S, Thorat D, et al. Hypoxia-driven osteopontin contributes to breast tumor growth through modulation of HIF1α-mediated VEGF-dependent angiogenesis[J]. Oncogene, 2014, 33(16):2053-2064.
[21] Cao Y, Guangqi E, Wang E, et al. VEGF exerts an angiogenesis-independent function in cancer cells to promote their malignant progression[J]. Cancer Res, 2012, 72(16):3912-3918.
[22] Guo R, Lu G, Qin B, et al. Ultrasound imaging technologies for breast cancer detection and management: A review[J]. Ultrasound Med Biol, 2018, 44(1):37-70.
[23] Vraka I, Panourgias E, Sifakis E, et al. Correlation between contrast-enhanced ultrasound characteristics (qua-litative and quantitative) and pathological prognostic factors in breast cancer[J]. In Vivo, 2018, 32(4):945-954.
[24] Cao XL, Bao W, Zhu SG, et al. Contrast-enhanced ultrasound characteristics of breast cancer: Correlation with prognostic factors[J]. Ultrasound Med Biol, 2014, 40(1):11-17.
[25] Wan CF, Du J, Fang H, et al. Enhancement patterns and parameters of breast cancers at contrast-enhanced US: Correlation with prognostic factors[J]. Radiology, 2012, 262(2):450-459.
[26] Putti TC, El-Rehim DM A, Rakha EA, et al. Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis[J]. Mod Pathol, 2004, 18(1):26-35.
[27] Zhao LX, Liu H, Wei Q, et al. Contrast-enhanced ultrasonography features of breast malignancies with different sizes: Correlation with prognostic factors[J]. Biomed Res Int, 2015, 2015:613831.
[28] Zhao YX, Liu S, Hu YB, et al. Diagnostic and prognostic values of contrast-enhanced ultrasound in breast cancer: a retrospective study[J]. Onco Targets Ther, 2017, 10:1123-1129.
[29] Lichtenbeld HC, Barendsz-Janson AF, Essen HV, et al. Angiogenic potential of malignant and non-malignant human breast tissues in an in vivo angiogenesis model[J]. Int J Cancer, 1998, 77(3):455-459.
[30] Ji CL, Li X, He Y, et al. Quantitative parameters of contrast-enhanced ultrasound in breast invasive ductal carcinoma: The correlation with pathological prognostic factors[J]. Clin Hemorheol Microcirc, 2017, 66(4):333-345.
[31] Szabó BK, Saracco A, Tánczos E, et al. Correlation of contrast-enhanced ultrasound kinetics with prognostic factors in invasive breast cancer[J]. Eur Radiol, 2013, 23(12):3228-3236.
[32] Nie M, Qin YC, Zhu JF, et al. Correlation between ultrasonic features and expression levels of C-erbB-2, VEGF and nm23 in breast cancer[J]. Oncol Lett, 2018, 16(2):1701-1707.
[33] 朱琳, 张丽华, 吴道明, 等. 超声光散射成像系统对各种病理类型乳腺病变的诊断价值[J]. 中国超声医学杂志, 2016, 32(10):883-886.
[34] Mostafa A, Vavadi H, Uddin KMS, et al. Diffuse optical tomography using semiautomated coregistered ultrasound measurements[J]. J Biomed opt, 2017, 22(12):1-12.
[35] Kim MJ, Su MY, Yu HJ, et al. US-localized diffuse optical tomography in breast cancer: comparison with pharmacokinetic parameters of DCE-MRI and with pathologic biomarkers[J]. BMC Cancer, 2016, 16(1):50.
[36] Zhi WX, Wang Y, Chang C, et al. US-guided diffuse optical tomography: Clinicopathological features affect total hemoglobin concentration in breast cancer[J]. Trasl Oncol, 2018, 11(4):845-851.
[37] Zhu Q, Hegde PU, Ricci A, et al. Early-stage invasive breast cancers: potential role of optical tomography with US localization in assisting diagnosis[J]. Radiology, 2010, 256(2):367-378.
[38] Choi JS, Kim MJ, Youk JH, et al. US-Guided optical tomography: Correlation with clinicopathologic variables in breast cancer[J]. Ultrasound Med Biol, 2013, 39(2):233-240.
[39] Brown JQ, Wilke LG, Geradts J, et al. Quantitative optical spectroscopy: A robust tool for direct measurement of breast cancer vascular oxygenation and total hemoglobin content in vivo[J]. Cancer Res, 2009, 69(7):2919-2926
文章导航

/